Trajectory Analysis of Symptom Distress and Cancer-related Fatigue After Adjuvant Chemotherapy in Breast Cancer Female

Taipei Medical University

Status: Not yet enrolling

Conditions: Symptom Distress During Breast Cancer Treatment

Treatments: Behavioral: breast adenocarcinoma receiving chemotherapy; Behavioral: Control-for

Study type: Observational

Funder types: Other

Identifiers

NCT04911699

symptom of breast cancer

Details and patient eligibility

About

When receiving adjuvant chemotherapy, a variety of symptoms will appear and it is very painful. These symptoms occur at the same time and are related to each other. The symptom distress may affect the patient's compliance with adjuvant chemotherapy and whether the adjuvant chemotherapy can be completed on schedule. Among the symptoms of trouble, cancer-related fatigue is the most common, and the incidence can be as high as 99%. In this study, I want to track the population of breast cancer patients receiving adjuvant chemotherapy, and women in the control group who receive only anti-hormonal breast cancer or carcinoma in situ. During the treatment period, at different time points, it also collects subjective symptom distress changes and changes. The study aimed cancer-related exhaustion is measured to gain a deeper understanding of the effects of symptom troubles suffered by patients during treatment. We also hoped that in the future, it can be provided to colleagues in clinical work and can be given to breast cancer patients receiving adjuvant chemotherapy and increased holistic care quality.

Enrollment: 120 estimated patients

Sex: Female

Ages: 20+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. The surgical pathological tissue report confirms that the diagnosis is zero stage breast carcinoma in situ women and stage I~III Breast cancer women.
2. Those who are admitted to the hospital for the first time adjuvant chemotherapy or hormonal therapy.
3. Age (inclusive) over 20 years old

Exclusion criteria

1. Women with breast cancer who are unconscious or unable to express.

Trial design

120 participants in 2 patient groups

breast adenocarcinoma

Description:

1. The surgical pathological tissue report confirms the diagnosis of breast adenocarcinoma women with stage I\~III 2. Those who are admitted to the hospital and receive adjuvant chemotherapy for the first time. 3. Age (inclusive) over 20 years old.

Treatment:

Behavioral: breast adenocarcinoma receiving chemotherapy

Control

Description:

1. The surgical pathological tissue report establishes women diagnosed as stage 0 to stage III breast cancer 2. Those who are admitted to the hospital to receive anti-hormonal drug treatment. 3. Age (inclusive) over 20 years old.

Treatment:

Behavioral: Control-for